81 results about "Pre-Therapy" patented technology

Systems and methods are disclosed for simulation of occluded arteries and / or optimization of occlusion-based treatments. One method includes obtaining a patient-specific anatomic model of a patient's vasculature; obtaining an initial computational model of blood flow through the patient's vasculature based on the patient-specific anatomic model; obtaining a post-treatment computational model by modifying portions of the initial computational model based on an occlusion-based treatment; generating a pre-treatment blood flow characteristic using the initial computational model or computing a post-treatment blood flow using the post-treatment computational model; and outputting a representation of the pre-treatment blood flow characteristic or the post-treatment blood flow characteristic.

The invention discloses a sugar chain marker combination for predicting prognosis of liver cancer transarterial chemoembolization and application of the sugar chain marker combination. The invention discovers and verifies that the combination composed of NA3Fb, NA4Fb and NA4F2b can be used as a novel marker for evaluating TACE treatment reaction and prognosis by analyzing a serum sugar chain map of a liver cancer patient for the first time. Based on the marker combination, a TACE-GT prognosis scoring model and system are established, and the progression risk of a patient within 12 months after a TACE operation can be effectively distinguished by noninvasively detecting the expression levels of three carbohydrate chains in serum of the patient and calculating a specific score. The detection method provided by the invention is based on a blood sample, and has the advantages of noninvasiveness and convenience, and a risk assessment system can provide individualized curative effect prediction and decision support for clinicians before and after TACE treatment, and has important values for realizing precise treatment of liver cancer and improving prognosis of patients.

Systems and methods are disclosed for simulation of occluded arteries and / or optimization of occlusion-based treatments. One method includes obtaining a patient-specific anatomic model of a patient's vasculature; obtaining an initial computational model of blood flow through the patient's vasculature based on the patient-specific anatomic model; obtaining a post-treatment computational model by modifying portions of the initial computational model based on an occlusion-based treatment; generating a pre-treatment blood flow characteristic using the initial computational model or computing a post-treatment blood flow using the post-treatment computational model; and outputting a representation of the pre-treatment blood flow characteristic or the post-treatment blood flow characteristic.

The invention belongs to the field of tumor medicine and the technical field of molecular biology and gene detection, and relates to application of rs17771861 in preparation of a nasopharyngeal carcinoma prognosis prediction marker, and the sequence of the SNP site rs17771861 is as shown in SEQ ID NO.1. The invention also relates to application of the SNP site rs17771861 in preparation of a nasopharyngeal carcinoma prognosis prediction marker. The invention provides an SNP (Single Nucleotide Polymorphism) marker rs17771861 related to nasopharyngeal carcinoma prognosis, application of the SNP marker rs17771861 and a detection kit capable of being used for nasopharyngeal carcinoma prognosis prediction, and the SNP marker rs17771861 is used for assisting in guiding individualized treatment and improving prognosis of tumor patients. After the kit disclosed by the invention is applied to clinical detection, prognosis of a patient can be evaluated before treatment, and a more positive and effective treatment scheme is formulated for the patient with poor prognosis, so that individualized treatment of the patient is realized, and the survival rate is increased. In addition, the kit only needs to detect peripheral blood, and has the characteristics of convenience in sampling, simplicity in operation, high timeliness and the like.

The invention discloses an in-vitro fertilization-based method and system for predicting the cumulative live productivity of multiple complete cycles, and the method comprises the steps: obtaining clinical data, embryo information and pregnancy follow-up visit data of a patient, and screening and preprocessing a sample in combination with a collection and discharge standard; feature variables are extracted before treatment, after treatment and at the early stage of pregnancy, an optimal set is determined, and key factors influencing live birth at all stages are accurately captured; after the nonlinear variables are processed by the RCS, a pre-treatment / post-treatment COX regression model and a Logistic regression model are adaptively constructed, and the prediction precision is improved by fitting data characteristics; and meanwhile, by evaluating the iterative optimization model, the variable weight is visually displayed by using a Nomogram graph after the model is qualified. The method can accurately predict the multi-cycle cumulative live productivity, assists a doctor in formulating a personalized scheme, helps a patient to reasonably plan treatment, reduces the time and economic burden of blind treatment, and has clinical practical value and benefits of the patient.

Disclosed herein is Differential Subclone Eradication and Resistance Analysis (DSER), a method developed to identify molecular targets for improved therapy by direct comparison of genomic features of eradicated and resistant subclones in pre-and post-treatment samples from a patient with BRCA2-deficient metastatic prostate cancer. FANCI and EYA4 were identified as candidate DNA repair-related targets for converting subclones from resistant to eradicable, and RNAi-mediated depletion of FANCI confirmed it as a potential target. The EYA4 alteration was associated with adjacent L1 transposon insertion during cancer evolution upon treatment. L1 activation was inhibited by the antiretroviral drug azidothymidine. In conclusion DSER provides an informative intermediate step toward effective precision cancer medicine, especially in cases with dramatic but temporary metastatic tumor regression. L1 transposon activation may be a modifiable source of cancer genomic heterogeneity, suggesting the potential of leveraging newly discovered triggers and blockers of L1 activity to overcome therapy resistance.

A vapor delivery system and method is provided that is adapted for treating prostate tissue. The vapor delivery system includes a vapor delivery needle configured to deliver condensable vapor energy to tissue. In one method, the vapor delivery system is advanced transurethrally into the patient to access the prostate tissue. The vapor delivery system is properly positioned by measuring and advancing the system based on a field-of-view of an endoscope or camera disposed within the system.

A vapor delivery system is provided that may include any of a number of features. One feature of the vapor delivery system is that it can apply condensable vapor energy to tissue, such as targeted tissue within a prostate, to shrink, damage, or denature the targeted tissue. In some embodiments, the vapor delivery system can include safety features including prostate capsule detection, needle alignment, deployment, and tracking, and treatment tracking. Mechanisms and methods for safe and effective treatment of prostate tissues are described herein.

1. The name of the design product: computer with graphical user interface (computing medical accelerator tumor center bed coordinates). 2. The use of the design product: graphical user interface in the screen. 3. The design points of the design product: graphical user interface in the screen. 4. The picture or photo that best shows the design points: front view. 5. The use of the graphical user interface: quickly and accurately calculate the coordinates of the accelerator bed corresponding to the tumor center of the tumor radiotherapy patient, and submit the coordinates to the radiotherapy technician to complete the accurate pre-treatment repositioning bed. 6. The human-computer interaction mode of the graphical user interface: in the lower half of the left half of the main view, input the size of the radiotherapy plan moving bed value, without considering the positive and negative signs before the number. Click on the orientation corresponding to the radiotherapy treatment single, such as left and right, front and back, head and foot direction, click Assign to the upper half of the left half of the calculation function module, and the specific signed value of the moving bed can be displayed in the calculation module. For the initial positioning of the radiotherapy patient, enter the initial accelerator bed value into the initial value module, click calculate, and display the final bed value corresponding to the final tumor center. Click on celar to zero the value of the calculation function module. Click on show to enlarge the result into a separate interface and provide the coordinates to the therapist.

The application relates to an intelligent temperature control moisturizing skin protection device for tumor radiotherapy patients, which comprises an intelligent humidifier body, a telescopic pipe fixedly connected to a liquid outlet of the intelligent humidifier body, a supporting bottom plate, a bearing disc rotatably connected to the surface of the supporting bottom plate, a cross trajectory groove and at least one radial hole formed in the bearing disc, the intelligent humidifier body arranged on the bearing disc, a transmission structure arranged in the supporting bottom plate and an auxiliary structure. The driving member drives the rotating column to continuously rotate, and a set of connecting rod mechanisms are used to convert the rotating motion into specific sector reciprocating swing of the contact wheel, the contact wheel drives the cross trajectory groove on the bearing disc, and finally drives the bearing disc and the intelligent humidifier on the bearing disc to intermittently rotate, so that the output of the moisturizing medium is no longer limited to before and after treatment, but can be continuously carried out during a single treatment lasting for dozens of minutes, and real-time and active protection of the skin is realized.

Radiofrequency ablation systems having a user interface. Pre-therapy planning and testing is performed and data gathered by the radiofrequency ablation system. A user interface for the radiofrequency ablation system displays anatomical mapping locations that have been tested, with indicia of testing outcomes including positive and negative outcome information and the type of testing performed.

A vapor delivery system and method is provided that is adapted for treating prostate tissue. The vapor delivery system includes a vapor delivery needle configured to deliver condensable vapor energy to tissue. In one method, the vapor delivery system is advanced transurethrally into the patient to access the prostate tissue. The vapor delivery system is properly positioned by measuring and advancing the system based on a field-of-view of an endoscope or camera disposed within the system.

Provided is a Pt(IV) complex. As a prodrug, the Pt(IV) complex is activated by irradiation to release a Pt(II) complex for the treatment of tumors. Also provided is a pharmaceutical composition including the Pt(IV) complex, and the use of the Pt(IV) complex in the preparation of a drug for treating tumors by means of irradiation activation. Further provided is a kit including the Pt(IV) complex and the description, wherein the description indicates that radiotherapy is performed after administration to treat tumors.

Radiofrequency ablation systems having a user interface. Pre-therapy planning and testing is performed and data gathered by the radiofrequency ablation system. A user interface for the radiofrequency ablation system displays anatomical mapping locations that have been tested, with indicia of testing outcomes including positive and negative outcome information and the type of testing performed.

This application relates to the field of biotechnology, specifically disclosing the application of immune cell subsets in the preparation of detection products for assessing the efficacy of neoadjuvant therapy and the risk of recurrence and metastasis in breast cancer. The detection method described in this application is non-invasive and convenient, requiring only peripheral blood, and is easy to repeat sampling and dynamic monitoring. This application also provides a predictive model for the efficacy of neoadjuvant therapy in breast cancer, and a predictive model for the risk of recurrence and metastasis in breast cancer treated with neoadjuvant therapy. The constructed predictive model has a high AUC value (0.82-0.87), and good sensitivity and specificity. Furthermore, through regular postoperative monitoring, abnormal dynamic changes in immune cell subsets can be detected, potentially indicating signs of recurrence earlier than imaging and traditional tumor markers. This helps identify advantageous populations before treatment and high-risk populations after treatment, enabling optimization of treatment plans and individualized adjustment of follow-up density.

The utility model discloses a leg fixing structure for radiotherapy, which relates to the technical field of leg fixing and comprises a base, two threaded rods are rotatably arranged in the base and are symmetrically arranged along the center line of the base, a belt is arranged on the outer surface of one side of each threaded rod, a rotating wheel is arranged in the middle of each belt, and the rotating wheels are arranged on the rotating wheels. The belt is located in the base, a rotary knob is fixedly arranged on one side of the rotating wheel, the rotary knob is rotationally connected with the base, and an internal thread block is arranged on the outer surface of the base in a meshed mode. Compared with an existing common leg fixing structure, the leg fixing structure for radiotherapy has the advantages that after legs of a patient are fixed on the device, when a knob is rotated, threaded rods on two sides can be driven by a belt, so that the position of an internal threaded block can be changed, and the position of the legs of the patient can be conveniently adjusted before treatment; the comfort of a patient can be guaranteed to a certain extent, and the affected part can be conveniently aligned with an instrument.

The invention discloses a method for predicting small cell lung cancer immunotherapy effect based on CT radiomics. The method comprises the following steps: firstly, carrying out lung enhancement CT scanning on a small cell lung cancer patient receiving immunotherapy before and after treatment, extracting radiomics characteristics and calculating delta-RF; in the aspect of model construction, 1037 radiomics features are extracted, and the model is constructed through a series of processing. The model display includes a variety of predictive indicators, such as an overall lifetime (OS), a progression-free lifetime (PFS), a complete remission (CR), a partial remission (PR), a column diagram, a consistency index, a subject working characteristic curve and its underlying area, a calibration curve, and a clinical decision curve. The model has a high C index and an AUC value for PFS and OS prediction, the AUC for curative effect prediction is 0.913, and a calibration curve is close to an ideal line. Compared with a prediction scheme based on NGS sequencing, the method has the advantages of being low in cost, non-invasive, efficient, dynamic, accurate and the like, and the image omics concept is used for predicting the curative effect of SCLC immunotherapy for the first time.

The present application relates to the technical field of medical apparatus and instruments, and discloses a neonatal hypothermia portable treatment device and a body temperature regulation system, aiming to solve the problem that the prior art cannot adapt to the transfer scene and is prone to body temperature out of control when a neonatal hypoxic-ischemic encephalopathy is transferred, the body temperature regulation system comprises four modules of information acquisition, temperature control decision, temperature control execution and information connection, the information acquisition module collects and discriminates body temperature, physiological parameters and transfer interference data; the temperature control decision module generates temperature control instructions and interference compensation strategies in combination with preset parameters of body weight and according to scenes; the temperature control execution module drives components to land on the ground according to instructions and feeds back the state; and the information connection module summarizes data and synchronously transfers the data into a hospital admission system, so that the transition body temperature is stably controlled during the transfer, the hospital admission first-aid operation is smoothly connected, and the technical blank of pre-treatment body temperature transition management during short-distance transfer is filled.

The application discloses a kind of information management method and related equipment for thyroid cancer postoperative iodine 131 treatment patient.It comprises: based on the treatment management data of patient, scheduling model is constructed with patient waiting time, medical interaction cost and isolation bed vacancy time as optimization target, and bed capacity constraint, clinical urgency constraint, radiation protection constraint and medical availability constraint are established;Based on the scheduling model and the constraint condition, the joint optimization of patient reservation admission batch, isolation bed allocation and medical communication task is carried out, and the treatment scheduling result is generated;In the case where patient temporary adjustment, bed state change or iodine 131 treatment preparation abnormality is monitored, the treatment scheduling result is dynamically rearranged, so as to execute patient reminder, treatment connection and follow-up management according to the treatment scheduling result after rearrangement.It can solve the problems of low efficiency of reservation and resource coordination, fragmented medical records and lack of dynamic tracking mechanism in traditional information management mode.

The invention discloses a PARP inhibitor sensitivity prediction method based on a specific cell cluster and application. The method comprises the following steps: acquiring an ovarian cancer tumor tissue sample of a subject; detecting whether a specific cell cluster exists in the sample or not, and determining the abundance of the specific cell cluster, wherein the specific cell cluster comprises an IFN epithelial cell cluster CN12 taking an IFN tumor cell as a center and / or a TAM enrichment cluster CN29 taking an M2 type tumor related macrophage as a center; according to the detection result, predicting according to at least one of the following rules: if the CN12 abundance before treatment is greater than 0.8%, the CN29 abundance before treatment is greater than 32.7%, the CN12 abundance after treatment is greater than 0.009%, the CN29 abundance after treatment is greater than 2.9%, or the SPP1 cell density before treatment is greater than 1.7%, predicting that the drug resistance is not sensitive or easily generated. The prediction model is established from a cell cluster space tissue level, and the method has the advantages of high prediction accuracy, flexible sample requirements, high operability and the like.

The invention discloses an application of a Gal-9 + Th cell and / or Gal-9 + Treg as an AIH detection target spot. Researches find that compared with a healthy control group, the peripheral blood Gal-9 + Treg cell proportion and Gal-9 + Th cell proportion of an AIH patient baseline group are remarkably increased, and after ALT of a patient in a treatment group returns to normal, the Gal-9 + Treg cell proportion and the Gal-9 + Th cell proportion are both decreased compared with those before treatment, and it is indicated that the Gal-9 + Treg cell proportion and the Gal-9 + Th cell proportion are effective indexes for monitoring disease improvement. However, the AIH is a chronic disease process, even if the ALT level returns to normal, Gal-9 + Treg cells and Gal-9 + Th cells still do not return to the level of a healthy control group, the Gal-9 + Th cells are taken as detection targets, the progress of the AIH disease course can be monitored more accurately, and disease repetition and biochemical rebounding caused by premature drug withdrawal are prevented.

Provided is a blood purification device. The pre-filling operation before treatment and the blood return operation after treatment are efficiently performed. The present invention is provided with: a liquid supply passage (11), one end of which is connected to a dialysate supply passage (4A) of a dialysate circuit and the other end of which is connected to a venous passage (3A) of a blood circuit; and a supply / discharge passage (12), one end of which is connected to the artery passage (3B) of the blood circuit, and the other end of which is switchably connected to the dialysate supply passage (4A) or the dialysate discharge passage (4B) of the dialysate circuit. In a state in which a circulation path is formed in which the tips of an arterial passage (3B) and a venous passage (3A) are connected to each other during a pre-charging operation, dialysate is supplied to a blood circuit via the feed passage (11), and the feed / discharge passage (12) is connected to the dialysate discharge passage (4B), and in a state in which a circulation path is formed in which the tips of the arterial passage (3B) and the venous passage (3A) are connected to each other, the feed / discharge passage (12) is connected to the dialysate discharge passage (4B). Dialysate is discharged from the dialysate supply path (4A) to the dialysate discharge path (4B) via the supply and discharge path (12) for supplying dialysate to a blood circuit.

A method of treating amyotrophic lateral sclerosis (ALS), includes: determining for a patient diagnosed with ALS, a pre-treatment amount of neurofilament light chain (NfL) in the patient's serum or plasma; orally administering to the patient a first rho kinase inhibitor in a predetermined amount for a predetermined period of time; determining a post-treatment amount of NfL in the patient's serum or plasma; when the post-treatment of amount of NfL is determined to be lower than the pre-treatment amount of NfL, orally administering to the patient a second rho kinase inhibitor in a therapeutically effective amount for treating ALS; and when the post-treatment of amount of NfL is determined to be not lower than the pre-treatment amount of NfL, withholding administration of the second rho kinase inhibitor to the patient.

The invention provides an anus suppository for treating prostatitis and a preparation method thereof, and relates to the technical field of pharmaceutical preparations. The anus suppository for treating prostatitis comprises an outer-layer sleeve and suppository contents, wherein the suppository contents comprise a heat-clearing and inflammation-diminishing layer, a warming, dredging and blood-activating layer and a qi-tonifying and kidney-tonifying layer which are sequentially distributed from outside to an inner core, and at least part of the suppository contents are wrapped by the outer-layer sleeve. The outer-layer sleeve prevents a large amount of medicine from being discharged after being released in a short time by delaying initial dissolution of a suppository matrix, and can contain dissolved suppository contents so as to prevent the dissolved suppository contents from flowing out of a body due to rectum peristalsis, so that the effective action time of the medicine is prolonged, and the curative effect of the suppository is improved. The medicine effect of the suppository content is fully exerted, and the use experience of a patient is improved; the medicine components permeate outwards at a controllable speed through the permeation part, the local effective medicine concentration of the rectum is maintained, the suppository matrix is gradually dissolved under the action of body temperature, and the traditional Chinese medicine composition is continuously released.

The present invention belongs to the field of biomedicine and specifically relates to a 5hmC molecular marker for predicting treatment sensitivity for sudden deafness. The present invention provides a 5hmC molecular marker for predicting treatment sensitivity for sudden deafness, comprising genes encoding the proteins CDK5R1, TAF6L, MFSD9, CDH7, PLCH1, MARCHF7, MCAT, MFNG, ATP9B, EGF, and EPHX2. The 5hmC molecular marker provided by the present invention can effectively predict treatment sensitivity for sudden deafness, with an AUC as high as 0.994. Using this molecular marker, treatment outcomes can be predicted before treatment, screening out patients with poor or ineffective treatment outcomes, allowing for preemptive comprehensive treatment and improving patient prognosis.

The invention discloses a prediction model for predicting a liver cancer combined treatment effect based on multi-mode MRI radiomics characteristics and a construction method and application thereof, and belongs to the technical field of liver cancer treatment effect prediction. In order to solve the problem that only part of liver cancer patients can benefit from an arterial chemoembolization combined targeted immunotherapy scheme at present, the invention proposes that before combined therapy, MRI radiomics characteristics and clinical factors are enhanced through noninvasive multi-modal comparison, multiple machine learning models are established, and the model learning model is used for learning the liver cancer patients. The tumor treatment response of arterial chemoembolism combined with molecular targeting and immunotherapy is predicted, and the applicability of the radiomics model is verified by using an external data set; besides, the radiomics model is combined with a clinical model, so that the method has more excellent prediction efficiency, and the radiomics features provide incremental prediction value for clinical factors. According to the method, the combined treatment effect of the liver cancer patients can be predicted, so that more effective and reasonable treatment schemes can be selected for different patients before treatment.

The invention discloses a kit for predicting the intracellular pH value of lung adenocarcinoma and the sensitivity of cisplatin treatment as well as a use method and application of the kit. According to the kit disclosed by the invention, the pH value in tumor cells of a patient is judged by detecting the expression quantity of ZNF266 in tumor tissues of the patient with lung adenocarcinoma, and the treatment effect of cis-platinum is predicted; the method is used for predicting the prognosis of a patient before treatment and evaluating the curative effect of a treatment scheme and the prognosis of the patient during and after treatment, so that precise medical treatment is realized. According to the invention, the method for predicting the pH value in the tumor cells of the patient and the cis-platinum treatment sensitivity by detecting the ZNF266 expression is proposed for the first time, the treatment scheme effect can be effectively evaluated, the individualized treatment of the lung adenocarcinoma patient is guided, the clinical benefit is improved, and meanwhile, unnecessary medical resource waste is avoided.

The present invention relates to a computer-implemented single time-point dosimetry method (200) comprising the following steps: a. Deriving for one or more organs at least one pre-therapy metrics from a pre-therapy scan of a patient (201); b. Deriving for the one or more organs the activity value at a specific time from a posttherapy scan of the patient (203); c. Computing the time-integrated activity value for the one or more organs (204); wherein the time-integrated value is computed based on the activity value from the posttherapy scan, the specific time of the posttherapy scan and a predicted effective half-life value, and wherein the predicted effective half-life value is determined by a machine learning-model trained according to the method of the present invention.

An example control device for performing a denervation procedure on a patient includes a memory and processing circuitry coupled to the memory. The processing circuitry is configured to receive, from one or more sensors and prior to delivery of neuromodulation therapy via a neuromodulation catheter, pre-therapy sensor data. The pre-therapy sensor data includes one or more parameter measurements for a period of time prior to the delivery of the neuromodulation therapy. The processing circuitry is configured to determine, based on the pre-therapy sensor data, whether the delivery of neuromodulation therapy would cause a deviation, in which the deviation includes one or more patient parameters or device parameters exceeding one or more patient parameter thresholds or device parameter thresholds, and transmit an output based on the determination.

The invention discloses application of ginseng and antler kidney tonifying tablets in preparation of drugs for preventing and / or treating prostatic hyperplasia. The ginseng antler kidney-tonifying tablet has a good treatment effect on prostatic hyperplasia, the treatment effect is remarkable, no operation is needed, the ginseng antler kidney-tonifying tablet belongs to new use of an old medicine, the safety is high, the side effect is small, and the production cost is greatly reduced. The problems that current western medicines for treating benign prostatic hyperplasia are long in medication cycle, large in toxic and side effects and limited in clinical application are solved. Experimental results show that the ginseng and antler kidney-tonifying tablet can reduce the prostate gland coefficient; the androgen level of a prostatic hyperplasia patient is reduced; the gland and glandular cavity expansion and hyperplasia degree of a prostatic hyperplasia patient is improved.